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Objective: To evaluate direct asthma-related costs in Swedish primary care in a real-life
setting.
Design: 12-month open-label study.
Setting: Swedish primary care in a real-life setting.
Participants: 1776 patients with persistent asthma.
Interventions: Patients with persistent asthma were randomised to one of three treatments:
a free adjustable combination of budesonide (100e400 mg/inhalation) and formoterol (4.5 or
9 mg/inhalation) via separate inhalers plus terbutaline as needed; budesonide/formoterol
(160/4.5 mg or 80/4.5 mg, two inhalations twice daily) plus terbutaline as needed; budeso-
nide/formoterol (160/4.5 mg or 80/4.5 mg, one inhalation twice daily or two inhalations once
daily), for maintenance plus additional inhalations as needed. Doses depended on previous
inhaled corticosteroid dose. Patients attended the clinic at 0, 1.5, and 12 months. Telephone
interviews were conducted at 4, 6, 8, and 10 months.
Main outcome measures: The primary endpoint was direct asthma-related healthcare costs.
Results: Statistically significant reductions in annual direct costs per patient were observed
with budesonide/formoterol maintenance and reliever therapy compared with the free adjust-
able combination of budesonide and formoterol (13%, P<0.001) and fixed-dose budesonide/
formoterol plus terbutaline (20%, P<0.001). Time to first severe exacerbation did not differ0 314 9944; fax: þ46 156 53533.
.mail.telia.com (B. Sta¨llberg).
8 Elsevier Ltd. All rights reserved.
Direct cost analysis for asthma in a real-life setting 1361significantly across treatment groups, with a mean reduction of 28% versus the free adjustable
combination of budesonide and formoterol (PZ0.076). Patients receiving budesonide/formo-
terol maintenance and reliever therapy used a significantly lower daily dose of budesonide
compared with the conventional (P<0.001).
Conclusions: This study reports direct cost savings with budesonide/formoterol maintenance
and reliever therapy compared with conventional treatment regimens with at least equivalent
efficacy.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Global asthma treatment guidelines recommend an inhaled
corticosteroid (ICS) for the treatment of persistent asthma
with a short-acting b2-agonist (SABA) as needed for symptom
relief. For patients not well controlled by this treatment,
addition of a long-actingb2-agonist (LABA) is recommended.
1
Budesonide/formoterol (Symbicort) as both mainte-
nance and reliever therapy (Symbicort SMART) promotes
the use of ICS in proportion to disease severity, with low
doses used during periods of asthma control and higher
doses used in response to breakthrough symptoms. This
ensures treatment of the underlying inflammation of
asthma with every inhalation. This treatment concept is
simple for patients to use2 and is one treatment option rec-
ommended in the latest Global Initiative for Asthma guide-
lines for use in patients not controlled on ICS alone.1
Budesonide/formoterol maintenance and reliever therapy
has been investigated in a number of large-scale clinical tri-
als3e9 and is approved for use in adult patients (18 years)
in the European Union.
Concerns have been raised regarding the impact of the
reliever therapy on total treatment cost in routine asthma
care since budesonide/formoterol costs more per inhala-
tion than SABA as reliever medication.10 Furthermore,
treatment with budesonide and formoterol in separate
inhalers may facilitate down-titration of the individual
components, resulting in lower total drug use and lower
costs compared with budesonide/formoterol as both main-
tenance and reliever.
Health economic evaluations using efficacy studies as
the primary data source have suggested that budesonide/
formoterol maintenance and reliever therapy is cost-effec-
tive compared with other treatment options recommended
in current guidelines.10e13 Studies primarily designed to
address clinical efficacy might, however, be associated
with a number of disadvantages when deriving conclusions
related to health economics.14 Although other studies
have assessed the efficacy of asthma therapies in a real-
life setting,15,16 none, to our knowledge, has used costs
as the primary endpoint in a study of real-life practice.
Thus, the aim of this 12-month Swedish study was to
evaluate the direct asthma-related costs incurred in
a real-life setting in primary care, with budesonide/formo-
terol maintenance and reliever therapy compared with two
conventional asthma treatment regimens: free adjustable
or fixed combinations of ICS and LABA plus SABA as needed.
Secondary objectives were to compare indirect costs and
investigate patient- and physician-reported outcomes, effi-
cacy, and safety in the treatment groups.Materials and methods
The Symbicort and Health Economics in a Real Life
Evaluation (SHARE) study was a 12-month, randomised,
open-label, parallel-group study (study code
NCT00259766). The primary endpoint was direct asthma-
related costs and the study was designed to minimise the
impact of the study procedure on the behaviour of both
physicians and patients, on patient treatment, and on
treatment cost.
Study design
The study evaluated three treatment alternatives.
(1) A free combination of budesonide (Pulmicort; Astra-
Zeneca, Sweden) Turbuhaler (100e400 mg/inhalation) and
formoterol (Oxis; AstraZeneca, Sweden) Turbuhaler (4.5
or 9 mg/inhalation) plus terbutaline (Bricanyl; AstraZe-
neca, Sweden) as needed (0.25 or 0.5 mg/inhalation) at
an appropriate dose according to asthma severity as judged
by the investigator. Budesonide and formoterol doses could
be adjusted up or down within the approved dose range
throughout the study at the discretion of the investigator.
However, in contrast to formoterol, budesonide was not
permitted to be completely withdrawn.
(2) Budesonide/formoterol 160/4.5 mg or 80/4.5 mg
(Symbicort; AstraZeneca, Sweden), depending on previous
ICS therapy, two inhalations twice daily plus terbutaline as
needed (0.25 or 0.5 mg/inhalation).
(3) Budesonide/formoterol 160/4.5 mg or 80/4.5 mg
(Symbicort), depending on previous ICS dose, one inhala-
tion twice daily or two inhalations once daily for mainte-
nance plus additional inhalations as needed (Symbicort
SMART; AstraZeneca, Sweden).
Budesonide/formoterol maintenance and reliever
therapy was investigated with both a twice-daily regimen
and a once-daily regimen to evaluate if either was superior
with respect to efficacy or patient compliance. However,
the main analysis, as defined by the study protocol,
compared the three treatment regimens using merged
data from the two budesonide/formoterol maintenance
and reliever treatment groups.
This study was conducted according to the Declaration
of Helsinki and Good Clinical Practice guidelines at 222
primary care centres and paediatric out-patient clinics (195
and 27, respectively) in Sweden. The study protocol,
patient information, and consent forms were approved by
an ethics committee. All patients gave written informed
consent. The first patient was enrolled on 5 April 2004 and
the last patient completed the study on 12 May 2007.
1362 B. Sta¨llberg et al.Patients had three scheduled clinic visits at 0, 1.5, and
12 months after randomisation. Furthermore, telephone
interviews were conducted by a trained independent
interviewer at 4, 6, 8, and 10 months (14 days). This
pre-empted the need for patient diaries and maximised
adherence to a real-life environment. Patients randomised
to receive any treatment including budesonide/formoterol
were stratified according to baseline ICS dose. Those previ-
ously treated with ICS 400e500 mg/day were allocated to
treatment with the budesonide/formoterol Turbuhaler
(80/4.5 mg delivered dose) and those previously treated
with ICS >500 mg/day were allocated to the budesonide/
formoterol Turbuhaler (160/4.5 mg delivered dose). Even
though all medications were prescribed by the investigator
for 1 year, the patient had to visit the pharmacy repeatedly
to collect the required drugs as in usual clinical practice. In
order to avoid any risk of additional medication costs
related to the study, both patients and county councils
were compensated after the patient completed the study.
In Sweden, county councils are responsible for funding
medical treatment as well as paying drug costs, but do
not carry the burden of sick-leave costs.
Patient characteristics
Male and female outpatients aged 12 years with a diag-
nosis of asthma as defined by the American Thoracic
Society17 and using a constant daily dose of ICS (400 mg)
for 30 days prior to randomisation were eligible for inclu-
sion. Patients were also required to have persistent asthma
and to be receiving daily maintenance treatment with
a free combination of an ICS and a LABA, or to be symptom-
atic despite regular use of an ICS alone. Study exclusion
criteria included treatment with a fixed combination of
budesonide/formoterol or salmeterol/fluticasone in the
year preceding randomisation. Patients using oral cortico-
steroids within the 30 days prior to randomisation, those
with a smoking history of >10 pack-years, and individuals
with any disease or disorder which may be affected by
study medication were also excluded from the study.
Randomisation and blinding
The randomisation scheme was computer generated at
AstraZeneca Research and Development, Alderley Park,
UK. At each centre patients were randomised strictly
sequentially as they became eligible. Coded envelopes
with individual treatment codes stating the treatment
allocation for each randomised patient were provided. Any
patient requiring >10 inhalations of as-needed medication
on any 1 day was instructed to contact the investigator.
Patient- and physician-reported outcomes
At visit 1, patients were provided with a copy of a five-item
asthma control questionnaire (ACQ),18,19 and at each subse-
quent contact were asked for their responses by the investi-
gator or the telephone interviewer. At each contact patients
were also asked to complete a questionnaire regarding their
asthma symptoms, ranging from ‘no symptoms’ to ‘very
severe symptoms’. At visits 1 and 3 patients were requested
to rate their asthma status according to a four-point scale,
ranging from ‘not at all controlled’ to ‘very well controlled’.
A physician-reported ‘treatment change’ was defined as
a change in the prescribed study medication outside the
study protocol and lasting for more than 30 days.Clinical effectiveness and safety
The measure to determine clinical effectiveness in the
cost-effectiveness analysis was the number of patients
suffering at least one exacerbation during 1 year. An exac-
erbation was defined as deterioration in asthma resulting in
a hospitalisation/emergency room visit or the use of oral
corticosteroids due to asthma. Any patient experiencing
more than three exacerbations was considered for a change
in maintenance medication.
Since the primary objective of the study was to capture
real-life costs and effects, collection and reporting of
adverse events was limited to serious adverse events
(SAEs) and discontinuations due to an adverse event
(DAEs). Previously, several studies have reported that
budesonide, formoterol, and budesonide/formoterol main-
tenance and reliever therapy are well tolerated in patients
with moderate to severe asthma.3e9
Cost-effectiveness analysis
The cost-effectiveness analysis was performed from
a county council perspective, taking into account only
direct costs as the primary endpoint and using number of
patients suffering at least one exacerbation as the effec-
tiveness measure. The study was not powered to capture
differences in asthma-related sick leave.
Healthcare resource utilisation
Direct resource use consisted of prescribed study medica-
tion collected from the pharmacy, use of other asthma
medication, number of contacts (telephone or visit) with
a nurse or physician due to asthma or treatment for
asthma, and number of asthma-related hospitalisations/
emergency room visits. Patients were required to record all
information related to the use of additional asthma
medication, sick leave related to asthma, or asthma-
related use of healthcare resources. Patients were asked
about any use of oral steroids at each visit and were
further asked at each telephone interview about any
hospitalisations/emergency room visits since last contact.
At each contact after visit 1, patients were also asked
about their use of asthma medication during the previous
24 h. The investigator was responsible for ascertaining all
medications and resources used during hospitalisations/
emergency room visits.
Patients were instructed to retain all used, unused, and
current drug medication containers both for study drug
collected from the pharmacy and for any additional
asthma medication. These were handed to the investigator
at visit 3. In addition, patients were instructed to record
any use of additional asthma medication or healthcare
resources. Investigators were also instructed to ask
patients at visits 2 and 3 regarding the use of any
additional asthma medication. Patients experiencing
a ‘treatment change’, as defined previously, were fol-
lowed for the entire study period as long as they remained
willing to participate. Scheduled study visits were omitted
from the resource use analysis as these were likely to have
been protocol driven and thus not representative of
normal clinical practice. Indirect asthma-related resource
loss comprised number of days absent from work for
employed patients or caregivers (<65 years) that were
due to the patient’s asthma.
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Costs were quantified in Swedish Kronor (SEK). Health-
care costs were calculated as the quantity of each
resource used multiplied by the corresponding unit cost
in SEK derived in 2006 (Table 1). In Sweden, current
regulations require that pharmacies provide the lowest-
priced substitutable drug, according to the list of substi-
tutable medicinal products defined by the Medical Prod-
ucts Agency, with the pricing system allowing prices to
change every month. As parallel importation of medicines
occurs widely in Sweden, it was decided to use the prices
actually paid for medicines in order to reflect the actual
costs incurred by the county councils and patients.
Hence, the unit costs used for medication reflect the
actual prices paid during 2006, including patients’ co-
payment. The unit costs were calculated by dividing
the total costs for the present drugs, provided by the
pharmacies during 2006, with the total number of
provided doses during the same period. Indirect resource
loss was measured as days of sick leave and was esti-
mated using the national average daily wage, including
social benefits. A part-time worker was assumed to
work 60% of full time.
Statistical and economic analysis
The sample size calculation was based on the primary
outcome variable. With a two-sided test, a significance
level of 5%, and a power of 80%, a sample size of 394
patients per treatment group was determined based on the
need to find a difference of 500 SEK (wV50) per patient.Table 1 Unit costs (SEK, year 2006 values)
Type of cost
Absence from work, assisting person, full-time worker
Absence from work, full-time worker
Absence from work, part-time worker
Telephone contact with physician
Telephone contact with nurse
Primary care physician
Nurse
Unplanned/emergency visit
Hospitalisation (general care unit), low specialised care
Budesonide/formoterol 80/4.5 mg
Budesonide/formoterol 160/4.5 mg
Budesonide/formoterol 320/9 mg
Formoterol 4.5 mg
Formoterol 9 mg
Terbutaline 0.25 mg
Terbutaline 0.5 mg
Budesonide 100 mg
Budesonide 200 mg
Budesonide 400 mg
a A full-time worker is assumed to work 8 h per day.
b A part-time worker is assumed to work 60% of full time.
c Assuming the same ratio as of visits.
d Ratio of visit to other healthcare contact/visit to physicianZ 0.4
e Assuming the same cost as a physician visit.
f Based on actual sales (including parallel import). $1.00Z SEK 5.8This difference was considered by the study advisory board
to be a relevant difference in cost between treatments for
the Swedish healthcare system. Analyses were based on the
full analysis set. All randomised patients who received at
least one dose of prescribed study medication and who
generated at least one data point after randomisation were
included in the full analysis set.
The group mean approach was used, in which means
were calculated as the sum of all resource use (and cost) in
the group divided by the total observation time for the
group (in days) and scaled to 1 year. Significance tests and
confidence intervals were calculated using the bootstrap
method, a re-sampling procedure.20 The costs were calcu-
lated from resource usage by applying defined unit prices,
which were defined prior to the clinical trial database being
locked for analysis. As the study did not assess outcomes or
costs after 12 months, discounting was not applied. The
secondary variables were analysed by analysis of covariance
with treatment and centre as factors and baseline value as
covariate. The efficacy variables (number of patients with
an asthma exacerbation and number of treatment failures)
were analysed using a CochraneeManteleHaenzel test.
Sensitivity analysis was conducted for each included cost
parameter by adjusting the base case unit price.
Results
Patient characteristics
A total of 1776 patients with persistent asthma were
enrolled and randomised, as shown in the CONSORTUnit Cost, SEK
Day 212622,23a
Day 212622,23a
Day 127622,23b
Contact 31324
Contact 12824c
Visit 82025d
Visit 33525
Visit 82024e
Bed day (inpatient) 609725
Dose 4.4026,27f
Dose 4.6726,27f
Dose 9.6826,27f
Dose 3.5226,27f
Dose 4.2326,27f
Dose 0.7626,27f
Dose 0.7426,27f
Dose 1.2826,27f
Dose 1.8826,27f
Dose 3.3926,27f
1.
95; V1.00Z SEK 9.304 xe.com, 23 May 2008).
1364 B. Sta¨llberg et al.diagram in Fig. 1. The treatment groups were well
balanced with respect to demographics, clinical status,
baseline ICS use (mean 641 mg/day), and previous LABA
prescriptions (Table 2). Results for both dosing regimens
of budesonide/formoterol maintenance and relieverFigure 1 Study design and patient flow. Figures in parentheses are
indicate patients who developed study-specific discontinuation crit
irrespective of whether they did or did not receive study treatme
least one dose of study medication and generated at least one dat
combination of budesonide and formoterol: Budesonide (100e400
rate inhalers (usual care in Sweden) (at an appropriate dose accord
butaline as needed. Fixed-dose budesonide/formoterol: Patients on
80/4.5 mg, two inhalations twice daily plus terbutaline as needed. P
moterol 160/4.5 mg, two inhalations twice daily plus terbutaline
therapy: Includes treatment with budesonide/formoterol one inha
two inhalations once daily plus as needed. Patients receiving 400e
terol 80/4.5 mg, one inhalation twice daily plus as needed or bud
as needed. Patients receiving > 500 mg ICS/day at randomisation re
daily plus as needed or budesonide/formoterol 160/4.5 mg, two in
were observed between results for the two budesonide/formoter
were equally effective. Furthermore, both once and twice daily d
reliever therapy are approved treatments in Sweden. The data f
therapy arms were therefore combined for analysis.treatment were combined, according to the study
protocol. No significant differences in any measured
baseline parameters were detected in a subgroup analy-
sis between the once-daily and twice-daily dosing
regimens.percent of patients randomised. Study discontinuation criteria
eria. Analysis sets. Safety Analysis Set: All patients randomised
nt. Full Analysis Set: All randomised patients who received at
a point after randomisation. Study protocols. Free adjustable
mg/inhalation) and formoterol (4.5 or 9 mg/inhalation) in sepa-
ing to asthma severity, as judged by the investigator) plus ter-
400e500 mg ICS/day at randomisation: Budesonide/formoterol
atients on > 500 mg ICS/day at randomisation: Budesonide/for-
as needed. Budesonide/formoterol maintenance and reliever
lation twice daily plus as needed and budesonide/formoterol
500 mg ICS/day at randomisation received budesonide/formo-
esonide/formoterol 80/4.5 mg, two inhalations once daily plus
ceived budesonide/formoterol 160/4.5 mg, one inhalation twice
halations once daily plus as needed. No significant differences
ol maintenance and reliever therapy arms and both protocols
osing regimens with budesonide/formoterol maintenance and
or the two budesonide/formoterol maintenance and reliever
Table 2 Patient demographics and characteristics
Free adjustable
combination of
budesonide
and formoterol
Fixed-dose
budesonide/
formoterol
Budesonide/
formoterol
maintenance
and reliever
therapy
No. of patients
Randomised 433 456 887
Full analysis set 433 452 884
Per protocol set 388 396 781
No. of adolescents (12e19 years) 66 65 127
Sex, % women 59 56 60
Mean age, years 43 45 43
Employment, n (%)a
Full-time 182 (42) 191 (42) 373 (42)
Part-time 61 (14) 47 (10) 118 (13)
Non-employedb 190 (43) 214 (47) 393 (45)
Peak expiratory flow, l/min 465 461 462
Forced expiratory volume in 1 second,
% predicted normal post-bronchodilator
96 97 95
Long-acting b2-agonist use, % 51 52 52
Inhaled corticosteroid, mg/day
400e500/>500, at inclusion, % 50/50 51/49 51/49
Daily dosec (SD) at inclusion 640 (285) 650 (315) 636 (293)
Daily dosed during treatment
(according to phone interviews)
550 368 291
a Based on full analysis set.
b Non-employed includes: student, house-person, retired/long-term sick leave, and unemployed.
c Metered dose.
d Delivered dose.
Direct cost analysis for asthma in a real-life setting 1365Healthcare resource utilisation and cost analysis
Few patients utilised non-medication healthcare resources
and no significant differences were observed in non-
medication resource use between the treatment groups
(Table 3). A total of 23% of patients visited their physician
during the study (excluding study visits) and 4% visited their
nurse. In addition, 15% and 6% of patients had telephone
contact with the physician or nurse, respectively. A total
of 15% of patients had an unscheduled emergency room
visit and only <0.5% were hospitalised due to asthma.
Annual direct costs per patient were significantly lower
with budesonide/formoterol maintenance and reliever
therapy compared with either the free adjustable combi-
nation of budesonide and formoterol plus SABA as needed
(795 SEK, P < 0.001) or the fixed-dose budesonide/formo-
terol plus SABA as needed (1335 SEK, P < 0.001) (Fig. 2).
Furthermore, analysis of direct-cost components showed
that >85% of direct costs were attributable to asthma medi-
cation in all treatment groups. The remaining direct costs
were predominantly comprised of asthma-related physician
visits and unscheduled emergency room visits (Table 4).
Sensitivity analysis was conducted for each included cost
parameter by adjusting the base case unit price. An
increase of 18% of the price for budesonide/formoterol
would offset the difference in total direct costs. Similarly,
a decrease in the price of budesonide by 28% or a decreaseof the formoterol price by 38% would offset the direct cost
difference. Changing any other unit price had a negligible
impact on the total direct costs.
The difference in total cost, including both direct and
indirect costs, did not reach statistical significance in any
comparison between treatment groups. However, the
study was not powered to capture any difference in
asthma-related sick leave and only a few patients were
cost drivers and contributed to the major part of the
indirect costs.
Exacerbations
No significant differences in the time to first exacerbation
were observed between the three treatment groups
(Fig. 3). A positive trend in favour of budesonide/formo-
terol maintenance and reliever therapy compared with
the free adjustable combination of budesonide and formo-
terol plus SABA as needed was observed (28% risk reduc-
tion; PZ 0.076). No statistically significant difference
was found between budesonide/formoterol maintenance
and reliever therapy and the fixed-dose budesonide/formo-
terol group (23% risk reduction; PZ 0.17). The rate of
severe exacerbations was similar in the three treatment
groups (Table 5). The percentage of hospitalisations/emer-
gency room visits and use of oral steroids were similar in
the three treatment groups.
Table 3 Resource use per patient per year by treatment group
Free adjustable
combination of
budesonide and
formoterol,
nZ 433
Fixed-dose
budesonide/
formoterol,
nZ 452
Budesonide/formoterol
maintenance
and reliever therapy,
nZ 884
Hospitalisation, days 0.010 0.000 0.007
Unplanned/emergency visits 0.295 0.346 0.448
Visit to primary care physician 0.811 0.466 0.511
Visit to primary care nurse 0.102 0.058 0.084
Telephone contact with physician 0.334 0.464 0.284
Telephone contact with nurse 0.120 0.146 0.152
Absence from work, days (patient) 1.874 1.266 2.317
Absence from work, days (assistant) 0.113 0.080 0.028
Number of inhalers
Budesonide/formoterol 80/4.5 mg 0 4.576 3.648
Budesonide/formoterol 160/4.5 mg 0.005 5.115 4.158
Budesonide/formoterol 320/9 mg 0 0.017 0.007
Budesonide 400 mg 2.487 0.008 0.004
Budesonide 200 mg 2.98 0.025 0.009
Budesonide 100 mg 0.026 0 0
Formoterol 9 mg 3.765 0.016 0
Formoterol 4.5 mg 5.038 0.008 0.01
Terbutaline 0.5 mg 1.118 1.052 0.003
Terbutaline 0.25 mg 0.724 0.715 0
1366 B. Sta¨llberg et al.Use of ICS and reliever medication
Patients receiving budesonide/formoterol maintenance and
reliever therapy used a significantly lower daily dose of
budesonide compared with either the free adjustable
combination of budesonide and formoterol plus SABA as
needed or with fixed-dose budesonide/formoterol plus
SABA as needed (P < 0.001); 291 mg/day (delivered dose),Figure 2 Direct asthma-related costs. $1.00Z SEK550 mg/day (estimated delivered dose), and 368 mg/day
(delivered dose), respectively (reported average use based
on the telephone interviews).
Patients used approximately 0.7 rescue inhalations in the
24 h prior to each contact in all treatment groups. There was
no difference in reported reliever medication use between
treatment groups and no change in the pattern of reliever
medication use was observed over the study period.5.895; V1.00Z SEK 9.304 xe.com, 23 May 2008).
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Direct cost analysis for asthma in a real-life setting 1367Patient- and physician-reported outcomes
Across all treatment groups, 55% and 24% of patients self-
rated their asthma status as being quite well-controlled or
very well-controlled at baseline, respectively. All treat-
ment groups experienced an improvement in asthma status
and asthma control questionnaire scores over the course of
the study with a similar change from baseline observed in
all treatment groups and no statistically significant differ-
ences between treatments.
Cost-effectiveness analysis
Budesonide/formoterol maintenance and reliever therapy
was associated with the lowest direct costs (Table 6), and
demonstrated the lowest number of patients suffering an
exacerbation, compared with the other two treatment
groups. The direct cost differences for budesonide/formo-
terol maintenance and reliever therapy compared with the
free adjustable combination of budesonide and formoterol
plus SABA and fixed-dose budesonide/formoterol plus SABA
were 13% and 20%, respectively (both P < 0.001). Calcu-
lation of the incremental cost-effectiveness ratio was not
relevant as budesonide/formoterol maintenance and
reliever therapy showed at least as good efficacy at lower
cost, hence being a cost-saving treatment option (Table 6).
Treatment change outside of protocol
More patients treated with budesonide/formoterol mainte-
nance and reliever therapy (PZ 0.004) and fixed-dose
budesonide/formoterol (PZ 0.014) were subjected to
changes in asthma medication outside the study protocol
for more than 30 days compared with those receiving the
free adjustable combination of budesonide and formoterol
(5%, 5%, and 2% of patients, respectively). Some patients
(approximately 2%) on budesonide/formoterol changed
back to previous care and received terbutaline as rescue
medication. There was no difference between treatment
groups in change of medication related to asthma
exacerbations.
Safety and withdrawals
All study treatments were well tolerated. The number
and type of SAEs and DAEs were low (66 SAEs and 71
DAEs in total) and similar between the treatment
groups and no clinically important differences were
observed.
Discussion
This pragmatic study demonstrates that budesonide/
formoterol maintenance and reliever therapy is at least
as effective as conventional treatment options for asthma
at a significantly lower cost and lower overall corticosteroid
load.
One of the benefits of this study was its reflection on
real-life practice without the rigorous selection and moni-
toring procedures typical of clinical trials. It is well known
Figure 3 Time to first asthma exacerbation.
1368 B. Sta¨llberg et al.that the enforced conditions in a randomised clinical trial
are unlikely to reflect the much less well-controlled clinical
practice setting and that any observed benefits may not
necessarily be equivalent in real life.15,16 Previously it has
been suggested that realistic estimates of costebenefit
relationships can only be obtained under conditions
approaching real life.15 Over the 12-month study period,
patients were only requested to attend the clinic on three
occasions and the majority of information was collected by
telephone interviews. Furthermore, patient instructions
were similar to ordinary instructions associated with
a prescription for asthma medication.
Recent studies of budesonide/formoterol maintenance
and reliever therapy have reported a significant reduction
in severe exacerbations together with preserved daily
asthma control at a lower overall steroid load compared
with salmeterol/fluticasone7,9 or budesonide/formoterol,7
both plus SABA as needed. The present study showed
a similar reduction in exacerbations as in previous studies,
however not statistically significant, with preserved overall
daily asthma control at a significantly lower daily dose of
budesonide. This study was powered based on the primaryTable 5 Exacerbation burden
Treatment groups
Free adjustable
combination of
budesonide and
formoterol,
nZ 433
Fixed-dose
budesonide/
formoterol,
nZ 452
Budesonide
formoterol
maintenanc
and relieve
therapy,
nZ 884
Patients with at
least 1
exacerbation, n (%)
46 (10.6) 45 (10.0) 68 (7.7)
No. of exacerbations
per 100 patients
per year
13.9 15.2 12.4outcome variable of direct asthma-related costs and thus
a considerably lower number of patients were randomised
than in previous studies designed to investigate the effec-
tiveness of budesonide/formoterol maintenance and
reliever therapy.
This study supports the notion that budesonide/formo-
terol maintenance and reliever therapy in one inhaler is at
least as effective as conventional treatment using separate
inhalers for ICS and LABA, and, moreover, can lead to
a significant reduction in costs. The observed cost differ-
ences can be considered reliable; estimates of the cost
savings available to a healthcare provider since direct costs
were the primary endpoint and the sensitivity analysis
showed stability for reasonable changes in unit price.
Furthermore, this study shows that down-titration of
budesonide and formoterol to the lowest effective dose
of each monocomponent is seldom practiced in real life.
Health economic analyses of previous clinical trials using
budesonide/formoterol maintenance and reliever therapy
indicate that this treatment approach is efficacious and
cost-effective,11e13 despite concerns that the use of bude-
sonide/formoterol as reliever might increase costs inTreatment comparison of risk and rate (95% CI); P-value
/
e
r
Budesonide/formoterol
maintenance and
reliever therapy vs.
free adjustable
combination of
budesonide and
formoterol
Budesonide/
formoterol
maintenance and
reliever therapy
vs. fixed-dose
budesonide/
formoterol
28% (51, 5);
PZ 0.07
23% (47, 12);
PZ 0.17
11% (34, 20);
PZ 0.75
19% (39, 9);
PZ 0.57
Table 6 Cost-effectiveness analyses
Free adjustable
combination of budesonide
and formoterol
Fixed-dose
budesonide/
formoterol
Budesonide/
formoterol maintenance
and reliever therapy
Patients with at least 1 exacerbation, % 10.6 10.0 7.7
Direct costs (SEK) 6014 6554 5218
Total costs (SEK) 8255 8620 8391
Direct cost change
Budesonide/formoterol maintenance and reliever therapy versus free adjustable combination
of budesonide and formoterol
795*
Budesonide/formoterol maintenance and reliever therapy versus fixed-dose budesonide/
formoterol
1335*
Incremental cost-effectiveness ratio
Budesonide/formoterol maintenance and reliever therapy versus free adjustable
combination of budesonide and formoterol
Cost saving
Budesonide/formoterol maintenance and reliever therapy versus fixed-dose budesonide/
formoterol
Cost saving
$1.00Z SEK 5.895; V1.00Z SEK 9.304 xe.com, 23 May 2008). *P < 0.001.
Direct cost analysis for asthma in a real-life setting 1369comparison to a generic SABA.10 In these studies budeso-
nide/formoterol maintenance and reliever therapy
emerged as dominant (greater efficacy at a lower cost)
compared with dose titration of salmeterol/fluticasone
plus SABA,11 fixed-dose salmeterol/fluticasone plus
SABA,12 and fixed-dose budesonide/formoterol plus
SABA.12 The cost savings reported with budesonide/formo-
terol maintenance and reliever therapy appear to be due to
reduced exacerbations and a lower overall dose of mainte-
nance medication, the benefits of which outweigh the
difference in reliever cost.10 The present study demon-
strates that budesonide/formoterol as reliever therapy
does not increase costs compared with SABA as reliever
medication.
Although the real-life trial design has several advan-
tages, it also has a number of inherent limitations. The
open-label format may raise concerns regarding the intro-
duction of bias. However, given the procedures used in this
study this should not be a major issue. For example,
patients were randomised in strict sequential order using
numbered, sealed randomisation envelopes containing the
allocated treatment regimen. Information was collected at
telephone interviews and not by standard patient diaries or
any electronic device. This may have affected the data
accuracy, but it is unlikely to have introduced any system-
atic bias leading to differences between treatment groups.
Assessment of medication use on the basis of inhalers
returned to the investigator at visit 3, rather than on the
basis of pharmacy purchase records, may suggest that
patients cannot be relied upon to return all their inhalers.
However, careful questioning ensured that this risk was
effectively minimised. Another potential limitation arises
from the decision not to track costs incurred in treating
adverse events not related to asthma. In theory, such costs
can form a significant proportion of all direct costs.
However, in this study the incidence of adverse events
was minimal, and similar between treatment groups, and
the cost of treating them could therefore be safelydisregarded. Lastly, the emphasis on a real-life environ-
ment for this study precluded the use of patient diaries,
meaning no record of symptom-free days was maintained.
However, it is likely that changes in the number of
symptom-free days have a minimal impact on direct costs
as exacerbations account for roughly half the total cost of
asthma care.21 Furthermore, patients who suffer frequent
exacerbations comprise approximately 20% of all patients
but incur up to 80% of the direct costs of asthma.21
In summary, this study demonstrates, in a real-life
setting, that budesonide/formoterol maintenance and
reliever therapy is a cost-saving treatment option with at
least equivalent efficacy at a lower corticosteroid load
compared with conventional asthma treatment.Conflict of interest statement
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